Contribution de la voie du TGFβ à la régénération hématopoïétique après chimiothérapie myélosuppressive

Fabienne Brenet; Joseph M. Scandura

doi:doi:10.1051/medsci/20132911003

Accès gratuit

Numéro		Med Sci (Paris) Volume 29, Numéro 11, Novembre 2013


Page(s)		940 - 942
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/20132911003
Publié en ligne		20 novembre 2013

Passegué E, Wagers AJ, Giuriato S, et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 2005 ; 202 : 1599–1611. [CrossRef] [PubMed]
Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006 ; 6 : 93–106. [CrossRef] [PubMed]
Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002 ; 30 : 973–981. [CrossRef] [PubMed]
Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 2000 ; 96 : 2022–2036. [PubMed]
Scandura JM, Boccuni P, Massagué J, Nimer SD. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci USA 2004 ; 101 : 15231–15236. [CrossRef]
Levéen P, Larsson J, Ehinger M, et al. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 2002 ; 100 : 560–568. [CrossRef] [PubMed]
Yaswen L, Kulkarni AB, Fredrickson T, et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 1996 ; 87 : 1439–1445. [PubMed]
Matsumoto A, Takeishi S, Kanie T, et al. p57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell 2011 ; 9 : 262–271. [CrossRef] [PubMed]
Brenet F, Kermani P, Spektor R, et al. TGF-beta restores hematopoietic homeostasis after myelosuppressive chemotherapy. J Exp Med 2013 ; 210 : 623–639. [CrossRef] [PubMed]
Yan Y, Frisén J, Lee MH, et al. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 1997 ; 11 : 973–983. [CrossRef] [PubMed]
Lyman GHJ. Impact of chemotherapy dose intensity on cancer patient outcomes. Natl Compr Canc Netw 2009 ; 7 : 99–108.
Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004 ; 3 : 1011–1022. [CrossRef] [PubMed]
Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002 ; 109 : 1551–1559. [PubMed]
Lataillade JJ, Brunet de la Grange P, Uzan G, Le Bousse-Kerdilès MC. Les cellules souches ont-elles l’âge de leur niche ? Med Sci (Paris) 2010 ; 26 : 582–585. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Passegué E, Wagers AJ, Giuriato S, et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 2005 ; 202 : 1599–1611. [CrossRef] [PubMed]

[2] Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006 ; 6 : 93–106. [CrossRef] [PubMed]

[3] Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002 ; 30 : 973–981. [CrossRef] [PubMed]

[4] Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 2000 ; 96 : 2022–2036. [PubMed]

[5] Scandura JM, Boccuni P, Massagué J, Nimer SD. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci USA 2004 ; 101 : 15231–15236. [CrossRef]

[6] Levéen P, Larsson J, Ehinger M, et al. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 2002 ; 100 : 560–568. [CrossRef] [PubMed]

[7] Yaswen L, Kulkarni AB, Fredrickson T, et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood 1996 ; 87 : 1439–1445. [PubMed]

[8] Matsumoto A, Takeishi S, Kanie T, et al. p57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell 2011 ; 9 : 262–271. [CrossRef] [PubMed]

[9] Brenet F, Kermani P, Spektor R, et al. TGF-beta restores hematopoietic homeostasis after myelosuppressive chemotherapy. J Exp Med 2013 ; 210 : 623–639. [CrossRef] [PubMed]

[10] Yan Y, Frisén J, Lee MH, et al. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 1997 ; 11 : 973–983. [CrossRef] [PubMed]

[11] Lyman GHJ. Impact of chemotherapy dose intensity on cancer patient outcomes. Natl Compr Canc Netw 2009 ; 7 : 99–108.

[12] Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004 ; 3 : 1011–1022. [CrossRef] [PubMed]

[13] Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002 ; 109 : 1551–1559. [PubMed]

[14] Lataillade JJ, Brunet de la Grange P, Uzan G, Le Bousse-Kerdilès MC. Les cellules souches ont-elles l’âge de leur niche ? Med Sci (Paris) 2010 ; 26 : 582–585. [CrossRef] [EDP Sciences] [PubMed]